重组人源性凝血因子Ⅶa治疗产后出血13例疗效分析被引量：7

下载PDF

导出

摘要目的探讨重组人源性凝血因子Ⅶa(r FⅦa)对产后出血患者的治疗效果。方法对13例产后出血常规止血治疗效果欠佳的患者,在输血的同时,加以r FⅦa 90μg/kg静脉滴注辅助治疗,视止血效果,最多再加r FⅦa两次,每次45μg/kg,若止血效果仍欠佳,行外科手术治疗。结果 13例产后出血常规止血治疗效果欠佳的患者,经r FⅦa治疗,有8例得到有效控制,有效率达61.54%(8/13),其凝血时间(PT)及凝血活酶时间(APTT)缩短,血红蛋白(Hb)、血小板数量(PLT)及纤维蛋白原(FIB)升高。结论 r FⅦa可有效治疗常规止血治疗无效的产后出血。

作者吴鹏桂培根黄菊芳

机构地区南华大学附属第二医院重症医学科衡阳市妇幼保健院重症医学科

出处《中南医学科学杂志》 CAS 2016年第2期209-210,223,共3页 Medical Science Journal of Central South China

关键词产后出血凝血因子Ⅶa 辅助治疗

分类号 R714.461 [医药卫生—妇产科学]

引文网络
相关文献

参考文献13

1Carroli G,Cuesta C,Abalos E,et al.Epidemiology of postpartum haemorrhage:a systematic review[J].Best Pract Res Clin Obstet Gynaecol,2008,22(6):999-1012.
2范建辉,陈新娟,滕奔琦,侯红瑛.重组活化凝血因子VIIa在产科出血中的应用[J].中国新药杂志,2011,20(6):523-525. 被引量：4
3蒋芳莲,罗俊标.人重组活化因子Ⅶa在难治性产后出血患者中的应用价值[J].医学临床研究,2014,31(7):1416-1417. 被引量：2
4Franchini M,Franchi M,Bergamini V,et al.The use of recombinant activated FVII in postpartum hemorrhage[J].Clin Obstet Gynecol,2010,53(1):219-227.
5Moscardo F,Perez F,de la Rubia J,et al.Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII[J].Br J Haematol,2001,114(1):174-176.
6Welsh A,Mc Lintock C,Gatt S,et al,Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage[J].Aust N Z J Obstet Gynaecol,2008,48(1):12-16.
7Lau P,Ong V,Tan WT,et al.Use of activated recombinant factor VII in severe bleeding-evidence for efficacy and safety in trauma,postpartum hemorrhage,cardiac surgery,and gastrointestinal bleeding.Transfus Med Hemother,2012,39(2):139-150.
8Isbister J,Phillips L,Dunkley S,et al.Recombinant activated factor VII in critical bleeding:experience from the Australian and New Zealand Haemostasis Register[J].Intern Med J,2008,38(3):156-165.
9Kobayashi T,Nakabayashi M,Yoshioka A,et al.Recombinant activated factor VII(r FVIIa/Novo Seven(R))in the management of severe postpartum haemorrhage:initial report of a multicentre case series in Japan[J].Int J Hematol,2012,95(1):57-63.
10Lavigne-Lissalde G,Aya AG,Mercier FJ,et al.Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage:a multicenter,randomized,open controlled trial[J].J Thromb Haemost,2015,13(4):520-529.

二级参考文献15

1World Health Organizations. The World Report 2005. Attending to 136 million birthstone ,every year. 2005. Make every mother and child count[ M]. Geneva: the World Health Organization, 2005: 62 - 63.
2DILDY GA. Postpartum hemorrhage: new management options [J]. Clin Obstet Gynecol, 2002, 45(2): 330-344.
3YAMAMOTO H, SAGAE S, NISHIKAWA S, et al. Emergency postpartum hysterectomy in obstetric practice[ J]. J Obstet Gynaecol Res. 2000. 26(5), 341 -345.
4KOJIMA H, ENDO K, MORIYAMA H, et al. Abrogation of mitochondrial cytochrome c release and caspase 23 activation in acquired multidrug resistance[ J]. J Biol Chem, 1998, 273 ('27) : 16647 - 16650.
5HAYNES J, LAFFAN M, PLAAT F, et al. Use of recombinant activated factor VII in massive obstetric haemorrhage [ J ]. Int J Obstet Anesth, 2007,16(1) : 40 -49.
6Kumar R, Gupta V. Disseminated intravascular coagulation: current concepts[J]. Indian J Pediatr, 2008, 75(7) : 733- 738.
7Mosardo F,Perez F, de al Rubia J, et al . Successful treatment of severe intro-abdominal bleeding associated with dissemina- ted intravascular coagulation using recombinant activated fac- tor':[J]. Br J Haematol, 2001,114(1) :174-176.
8Obieszczy KS, Brebborowicz GH, Platicanov V, et al . Recom- bi-nantfactor VII in the management of postpartum bleeds=an audit of clinica use[J]. Acta Obstet Gyneco! Scand, 2006,85 (10) :1239-1247.
9Franchini M, Franchi M, Bergamini V, et al . A critical re- view on the use of recombinant factorVIII a in life-threatening obstetric postpartum hemorrhage[J]. Semin Thromb Hemost, 2008,34(1) :104 -112.
10Mittal S,Watson HG. A critical appraisal of the use of recom- binant factor : a in acquired bleeding conditions[J]. Br J Haematol, 2006,133(4) :355-363.